A Massachusetts biopharma giant is at the center of preparations already underway if bird flu mutates and begins to find ...

The U.S. government will pay the vaccine maker Moderna $176 million to accelerate development of a pandemic influenza vaccine that could be used to treat bird flu in people, as concern grows about ...

Moderna is the only company in its peer group burning cash at an alarming rate. Click here to read more about MRNA stock and ...

While some of the initial zeal around localized vaccine production in Africa has waned since the height of the COVID-19 pandemic, efforts to bolster the continent’s immunization autonomy—especially | ...

We recently compiled a list of the 10 Firms Fall Amid Disappointing Earnings Performance. In this article, we are going to ...

Valued at $13.1 billion by market cap, Cambridge, Massachusetts-based Moderna, Inc. (MRNA) operates as a clinical-stage ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...

Discover how scientists developed a COVID-19 vaccine in record time using mRNA technology, leading to improved public health ...

The fusion of mRNA technology with AI has laid the foundation for ushering in a new era of cancer care. However, conducting ...

Artificial intelligence (AI) is transforming various industries as a major investing theme in 2025. The technology's ability ...

mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringes Canada is the fourth jurisdiction to approve mRESVIA ...

Volunteers in north Wales are among 25,000 people taking part in a global trial to find a vaccine against the symptoms of the winter vomiting bug, norovirus. The virus affects about four million ...